Ascletis Pharma Inc.
ASCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.16 | -0.21 | 0.02 |
| FCF Yield | -19.65% | -12.74% | -3.80% | -442.13% |
| EV / EBITDA | -2.28 | -7.62 | -5.82 | 14.51 |
| Quality | ||||
| ROIC | -14.94% | -12.74% | -13.48% | -8.21% |
| Gross Margin | 57.29% | 45.92% | -45.65% | 50.96% |
| Cash Conversion Ratio | 1.14 | 1.00 | 0.45 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -71.27% | -9.70% | 15.61% | -23.76% |
| Free Cash Flow Growth | -110.46% | -4.12% | -1.77% | -24.43% |
| Safety | ||||
| Net Debt / EBITDA | 2.20 | 2.55 | 8.67 | 14.72 |
| Interest Coverage | 0.00 | -2,084.78 | -2,190.94 | -1,799.73 |
| Efficiency | ||||
| Inventory Turnover | 0.13 | 5.04 | 3.84 | 0.67 |
| Cash Conversion Cycle | 4,354.87 | 99.69 | 241.64 | 788.70 |